Close

Cassava Sciences (SAVA) Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease

Go back to Cassava Sciences (SAVA) Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
(NASDAQ: SAVA) Delayed: 20.42 --0 (-0%)
Previous Close $20.42    52 Week High
Open $20.42    52 Week Low
Day High $20.42    P/E N/A 
Day Low $20.42    EPS
Volume